SCHEMBL297652

SCHEMBL297652

CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#N)cc23)c1F

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 12/20 0.84
CYP2C9 P11712 11/20 0.84
CYP3A4 P08684 4/20 0.84
BRAF P15056 3/20 0.78
RIPK2 O43353 2/20 0.78
RAF1 P04049 2/20 0.78
KDR P35968 2/20 0.78
MAP2K2 P36507 2/20 0.78
TGFBR2 P37173 2/20 0.78
NEK2 P51955 2/20 0.78
MAP2K1 Q02750 2/20 0.78
TNK2 Q07912 2/20 0.78
MAP2K5 Q13163 2/20 0.78
PTK6 Q13882 2/20 0.78
NEK11 Q8NG66 2/20 0.78
MAP3K20 Q9NYL2 2/20 0.78
MAP4K5 Q9Y4K4 2/20 0.78
BMPR1B O00238 1/20 0.78
PLK4 O00444 1/20 0.78
PIR O00625 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29915108 1.00 CYP2C19 (0.84) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL7877605 0.94 CYP2C19 (0.74) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL16568583 0.92 CYP2C19 (0.85) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL29898545 0.91 CYP2C19 (1.00) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL293605 0.91 CYP2C19 (1.00) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL2162873 0.91 BRAF (0.82) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL298926 0.90 CYP2C19 (0.69) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL2021100 0.89 CYP2C19 (0.83) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL20408833 0.89 CYP2C19 (0.75) CYP2C19CYP2C9CYP3A4BRAFRIPK2
SCHEMBL298473 0.89 CYP2C9 (0.67) CYP2C19CYP2C9CYP3A4BRAFRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406259-A1 PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES PLEXXIKON, INC. (US) 2012-01-18 EP claimed
US-8901301-B2 Pyrrolo[2,3-]pyridine kinase inhibitors PLEXXIKON INC. (US) 2014-12-02 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
EP-2406259-A1 PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES PLEXXIKON, INC. (US) 2012-01-18 EP disclosed
EP-2406259-A1 PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES PLEXXIKON, INC. (US) 2012-01-18 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
US-20100286178-A1 COMPOUNDS AND USES THEREOF PLEXXIKON INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP2C19 2730/4885CYP2C9 2176/4885CYP3A4 3611/4885
US-20100286178-A1 COMPOUNDS AND USES THEREOF BRAF, RAF1, FER CYP2C19 3265/4885CYP2C9 2194/4885CYP3A4 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.